CDA and acute myeloid leukemia: Guadecitabine is a dinucleotide of decitabine and deoxyguanosine, administered sub-cutaneously and developed to resist cytidine deaminase degradation, which has shown activity in both naive and R/R AML patients, with CR rate of 50% and 23%, respectively [178,179].